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Introduction
Europe
Objective: A competent vector of dengue and chikungunya viruses, Aedes albopictus, is present in Europe.
As a ﬁrst step towards assessing the likelihood of local transmission of these viruses in Europe, we estimated
the number of viremic person-days among air-travellers arriving in the European Union (EU).
Methods: For dengue, we developed a Monte Carlo model with the following parameters: probability
distributionsbasedonquarterly incidences in endemiccountries (years 2003–2007), passengerﬂow fromendemic
toEUcountries (year2006), durationof viremia, probabilityof beingviremicuponarrival, distributionandperiodof
vector activity in the EU. For chikungunya, due to scarce incidence data,wedevelopedamodelwithpoint estimates.
Results:Weestimatedat 4763 (range3067–7019) themediandengueviremicperson-days in2006withhighest
estimate among travellers from Asia during the third quarter. Dengue estimates among travellers arriving in EU
Aedes-infestedareas fromApril toOctoberwere 169viremic person-days,130 arriving in Italy. For chikungunya,we
estimated 6 viremic person-days in EU Aedes-infested areas among air-travellers from India; all occurred in Italy.
Conclusion: Our results are a ﬁrst step towards a real estimation of the risk of local dengue transmission in
Europe. Further research is needed to better understand vector capacity and other factors related to virus
transmission in temperate climates. Information on personal protection to travellers, early diagnosis and
implementation of vector monitoring and control should be a priority in EU areas where the vector is established.© 2009 Elsevier Inc. Open access under CC BY-NC-ND license.IntroductionDengue (DENV) and chikungunya viruses (CHIKV) are arthropod-
borne viruseswhich share similar epidemiological features. Both viruses
are endemic in the tropics and are transmitted to humans through the
bite of infected Aedesmosquitoes. During recent years, the incidence of
both dengue and chikungunya fever has risen worldwide (Rigau-Perez
et al., 1998; Ravi, 2006). There is no vaccine available for either virus and
prevention relies entirely on mosquito control and personal protection.
Dengue viruses, family Flaviviridae, genus Flavivirus, include four
serotypes 1, 2, 3 and 4. The infection is characterised bya sudden onset of
a self-limiting ﬂu-like illness, fever for 2–7 days, intense headache,
muscular and joint pains, retro-orbital pain, anorexia, nausea, vomiting
and rashes. The incubationperiod is 3 to14days, usually lasting4–7days.
More severe forms of the disease, such as dengue hemorrhagic fever and
dengue shock syndrome can occur. Case fatality can reach 50% if severe
forms are not treated (Dayal-Drager, 2004)., Département des Maladies
, France. Fax: +33 1 4179 6769.
sso).
ND license.Chikungunya virus belongs to the family of Togaviridae, genus Al-
phavirus. Chikungunya fever is a self-limiting febrile disease, similar to
dengue fever. Joint pains however are more marked, primarily
affecting the wrist, knee, ankle and small joints of the extremities,
and may last days to months. The incubation period is 2 to 12 days.
Chikungunya hasbeen re-emerging in Sub-SaharanAfrica since 2004
(Peyreﬁtte et al., 2007; Gravier et al., 2007; Sergon et al., 2008; Gould
et al., 2008). The largest ever documented chikungunya outbreak
occurred in 2005–2007 in the Indian Ocean islands (Renault et al.,
2007; Sergon et al., 2007; Ramchurn et al., 2008; Sergon et al., 2008;
Sissoko et al., 2008) and India (WHO, 2007; Mavalankar et al., 2007).
CHIKV transmissionwas also recently reported in Indonesia (Laras et al.,
2005),Malaysia (Soon et al., 2007) and Singapore (ProMED-mail, 2008).
Although not considered a life-threatening disease, severe forms of
chikungunya infection were described and co-morbidity with chikun-
gunya infectionwasmentioned in death certiﬁcates during the 2005–06
epidemic in Reunion island (Renault et al., 2007).
Aedes aegypti is the most competent vector for both dengue and
chikungunyaviruses (Dayal-Drager, 2004; Shope andMackenzie, 2004).
Present in Southern Europe in the ﬁrst half of the 20th century this
species was indicated as the main vector during the 1927–28 dengue
epidemic in Athens (Rosen, 1986). Eliminated then from continental
Fig. 1. Geographical distribution of Aedes albopictus in Europe, by province, 2007. Source: Scholte and Schaffner (2007).
176 T. Seyler et al. / Epidemics 1 (2009) 175–184Europe, re-establishment has not been reported since. A. aegypti has
been conﬁrmed since 2004–2005 in theAutonomousRegionofMadeira,
a Portuguese Island in the Atlantic Ocean (Almeida et al., 2007).
By the end of 2007, Aedes albopictus has been observed in certain
areas of the following European Union (EU) Member States: Italy,
Slovenia, Spain, France, Greece, The Netherlands and Germany (Fig. 1).
A. albopictus was pointed out as the main vector during the
chikungunya epidemic in the Reunion island, where a single virus
mutation was associated with a signiﬁcant increase of CHIKV
infectivity for A. albopictus (Tsetsarkin et al., 2007), and during the
only up-to-date chikungunya epidemic in Europe (Rezza et al., 2007).
Air-passenger ﬂow to the EUMember States rose from 20.2 million
in 2003 to 27.5 million in 2006 from dengue endemic countries, and
from 5.9 million in 2003 to 7.7 million in 2006 from countries
reporting recent chikungunya infections.
Considering the presence of A. albopictus and the potential of
introduction of A. aegypti in continental Europe, together with the
increasing number of overseas travellers, EU Member States should
consider the risk of introduction and transmission of both DENV and
CHIKV in Europe a potential public health issue (ECDC, 2006).
This study aimed to estimating the number of days during which
travellers from endemic countries are viremic with DENV and
CHIKV upon arrival in the EU in 2006, both in terms of space
(Aedes-infested countries and provinces) and time (seasons during
which the vector is active), as a ﬁrst step towards estimating the
likelihood of local transmission of DENV and CHIKV within con-
tinental Europe.
Methods
The model
To estimate the number of DENV and CHIKV viremic person-days
among air-travellers arriving during each quarter of 2006 in EU
Member States, we developed a model (Eq. (1) below). The year 2006
was chose because it was the most recent year with more complete
available disease incidence and air-traveller data.The estimated number of viremic person-days (V) among air-
travellers arriving from an endemic/epidemic country (c) to an EU
Member State (j) during each quarter (q) was a function of:
(i) the cumulative disease incidence rate [I] in each endemic/
epidemic country [c] for each quarter [q];
(ii) the estimated proportion of asymptomatic infections [a];
(iii) the likelihood for an infected individual of being viremic at the
moment of travelling [t];
(iv) the quarterly number of air-passengers [P] from each endemic/
epidemic country [c] to each EU Member State [j];
(v) the duration of viremia [D].
We assumed that mildly symptomatic and asymptomatic infec-
tions were not detected by local surveillance systems. We assumed
that symptomatic, mildly symptomatic and asymptomatic infections
were equally potential source of transmission to mosquitoes. We
applied infection incidence (disease incidence adjusted for asympto-
matic and mildly symptomatic infections) to passenger ﬂows, as if
passengers were a random sample of the local population.
The likelihood of an infected person being viremic when ﬂying or
soon after was estimated as a time fraction of the quarter during
which an infected person would be viremic. Since we used quarterly
incidences and a ﬁxed duration of 7 days viremia for both dengue and
chikungunya (see below), the likelihood of being viremic used in the
model was 7 days out of the 91.25 days in a quarter. The parameter [t]
was therefore 0.0767 for both DENV and CHIKV. For this we assumed
that the likelihood of being viremic was constant throughout the
quarter. We also assumed that viremic travellers took the plane on
average half way through their viremic period and spent therefore half
of their viremia in Europe.
VqcYj =
Iqc
1− a × t × P
q
cYj ×
D
2
ð1Þ
In the absence of detailed information on intra-national mobility, we
assumed that air-travellers arriving in an EU Member State were
distributed across the territory according to the underlying population
Table. 1
Estimation of population living in Aedes albopictus-infested area by EUMember State as
to December 2007.
EU member state Proportion of population
living in Aedes-infested
areas (%)
Description of the area
Italy 80 Almost all Italian territory
Slovenia 18 Primoska and Ljubliana
Spain 8 Barcelona and Alicante and
Tarragona municipalities
France 2 Districts of Alpes-Maritimes,
Var and Haute-Corse
Greece 1.5 Corfu island
The Netherlands 0 Only inside green houses
Germany 0 Eggs collected in ovitraps in
Baden-Württemberg, no adult
activity documented
Box 1
Parameters used to build the gamma distribution.
For each real distribution:
• Shape=mean^2/variance
• Scale=variance/mean
Minimum and maximum values of each real distribution were
also used as limits of the gamma distribution.
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days spent in EU Aedes-infested areas [Vc→jq ], we therefore adjusted
the quarterly estimates [Vc→jq ] for the proportion of each EU Member
State population living in Aedes-infested areas [mj] (Eq. (2) below).
VqcYmj = V
q
cYj × mj ð2Þ
We included in themodel only endemic/epidemic countries for which
combined data on disease incidence and air-passenger ﬂow were
available. We include in the model all 27 EU Member States, including
Romania and Bulgaria although in 2006 these two countries were not
EU Member States yet. Deﬁnition, values and sources of each
parameter used in the model are provided in Appendix A.
Geographical distribution and activity period of A. albopictus in Europe
We reviewed entomological publications and reports to identify
European areas (3rd administrative level) where potential vectors
were established. In particular, we used the latest available map
indicating EU areas where A. albopictus was established up to 2007
(Scholte and Schaffner, 2007). We estimated the proportion of the
national population living in Aedes-infested areas using demographic
data for EU member states provided by Eurostat.1 Estimation
proportions presented in Table 1 were used to compute viremic
person-days spent in Aedes-infested areas for each EU Member State.
Quarters during which A. albopictus is active were considered
quarter 2 (April to June) and quarter 3 (July to September) (Di Luca et
al., 2001; Toma et al., 2003).
Disease incidence
We ﬁrst reviewed publications made available on PubMed, the
World Health Organization, the USA Centres for Disease Control and
Prevention and surveillance reports at the Tropical and International
Department at the French Heath Surveillance Institute, in order to
identify countries where autochthonous dengue and chikungunya
cases had been reported at least once from 2003 to 2007 inclusive.
We then searched for quarterly incidence data for these countries
through WHO regional ofﬁces, WHO Dengue Network and national
Ministries of Health.When for one country only annual incidenceswere
available, we distributed annual cases to each quarter proportionally to
the quarterly case distribution of a neighbouring country for which
documented quarterly incidences were available. For this purpose, we
classiﬁed countries into the following regions: Asia: South-East Asia
mainland, South-East Asian islands, South Asia, China and Taiwan;
Africa: East African islands; America: South America highlands and
lowlands, Central America and The Caribbean.We did not ﬁnd incidence1 http://epp.eurostat.ec.europa.eu/portal/page/portal/population/data/database.data for countries in the Middle East, Sub-Saharan Africa and Oceania.
Paciﬁc islands had intensewell documented but sporadic epidemics and
were too far apart to estimate quarterly incidences.
Quarterly cumulative incidence rates were computed in countries
endemic for dengue and chikungunya using the 2005 demographic
estimates prepared by the United Nations Department of Economics
and Social Affairs, available online (Department of Economic and
Social Affairs — Population Division, 2005).
For dengue we developed quarterly incidence distributions for
2006 based on the 2003–2007 incidences, in order to take into
account some degree of reporting uncertainty. Quarterly incidence of
countries with similar ranges and seasonal patterns were aggregated
into geographical groups. We therefore built one incidence distribu-
tion for each quarter for 16 geographical groups (Appendix B).
Countries with occasional missing data were included. Countries with
limited or no data available for the whole period were excluded. A
gamma distribution function (see parameter details in Box 1) was
applied using R freeware2 to obtain theoretical probability distribu-
tions which best ﬁtted the real incidence distributions of each quarter
and group of countries. We then ran one thousand Monte Carlo
simulations with the parameters listed above to obtain quarterly
viremic person-days distribution estimates for each endemic/epi-
demic country and each EU country of destination.
We were unable to compute incidence distributions for chikungu-
nya due to scarce data. We therefore used point incidence, instead of
incidence distribution.
Asymptomatic infections and viremic period
Proportions of asymptomatic or mildly symptomatic dengue
infections may range from 75.7% to 90.2% (Burke et al., 1988; Endy
et al., 2002; Porter et al., 2005). We used in our model a ﬁxed value of
80% asymptomatic or mildly symptomatic dengue infections.
Studies carried out in Indonesia (Laras et al., 2005), Comoros
(Sergon et al., 2007) and Reunion Island (Perrau et al., 2007)
estimated the proportion of asymptomatic chikungunya infections
between 10% and 15.7%. For chikungunya, we used a ﬁxed 15% as the
proportion of asymptomatic or mildly symptomatic infections.
An infected person remains infectious as long as the virus
circulates in his/her blood at titres high enough to infect a female
mosquito taking a blood meal. The duration of dengue viremia in
humans has been documented including 1–2 days before the onset of
symptoms and 4–6 days for most of cases after the ﬁrst symptoms
(Gubler et al., 1981; Vaughn et al., 1997; Dayal-Drager, 2004). The
duration of chikungunya viremia is not well documented and we
assumed to be similar to the duration of dengue viremia. Considering
a worse scenario for this parameter, we used in our model a ﬁxed
duration of viremia of seven days for both infections.
Air-passengers ﬂow
Data on air-passenger ﬂow were obtained from Eurostat (free of
charge online database of the Statistical Ofﬁce of the European2 http://www.r-project.org/.
Fig. 2. Number of non-EU countries and overseas EU territories with reported DENV autochthonous infections, available dengue incidence for 2003–2007 and available passenger
data ﬂow for 2006.
Fig. 3. Distributions of quarterly estimated dengue viremic person-days by major
endemic areas for travellers arriving in all 27 European Member States, 2006. Note: The
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database maintained by the International Civil Aviation Organisation.
Both databases record direct ﬂight passengers.3 For each air route, the
highest number of passengers reported by either of the two databases
was kept in the model. We accessed the Passenger Intelligence
Services database (PaxIS) from the International Air Transport
Association for 2 pairs of countries (passengers arriving in Italy from
India and Reunion Island). This database also takes into account
indirect ﬂights4 and served as a model input to estimate chikungunya
viremic person-days arriving in Italy. Access to the PaxIS database
for all countries was not possible due to budget constraints.
Results
Dengue viremic person-days estimates
A total of 98 non-EU countries and overseas territories of EU
Member States were identiﬁed reporting dengue autochthonous cases
at least once between 2003 and 2007. Combined quarterly dengue
incidence and air-traveller data were available for 47 countries (48%)
on which the estimates below were based (Fig. 2).
For 2006, a median of 4763 dengue viremic person-days (range:
3067–7019; 25–75% inter-quartiles: 4368–5195) was estimated to be
spent in the27 EUmember states by air-travellers arriving from endemic
countries. Estimates were higher in the third quarter (median: 1376
viremic person-days) and subsequently in the ﬁrst, second and fourth
quarters (medians: 1312, 985 and954 viremic person-days respectively).
Thehighest estimateswere among travellers fromAsiancountries during
the third quarter (median: 740 person-days), followed by travellers from
South America during the ﬁrst quarter (median: 579 person-days), and
again Asian countries during the second and the ﬁrst quarters (medians
519 and 475 person-days respectively). The lowest estimates were
among travellers from the Caribbean and Central America during any of
the four quarters of the year (medians 30 to 168 viremic person-days)
(Fig. 3; for single country's estimates, see Appendices C and D).
During the two combined quarters during which A. albopictus is
active in Europe (April to September included), a median of 169
dengue viremic person-days was estimated being spent in Aedes-
infested areas (range: 85 and 307; 25%–75% inter-quartiles: 145–199
person-days). The median estimate was lower in the second (75
person-days) than in the third quarter (92 person-days). During the3 A passenger ﬂying from India to Italy with a connecting ﬂight in Kuwait was
reported in Eurostat and OFOD databases as a passenger arriving in Italy from Kuwait.
4 A passenger ﬂying from India to Italy with a connecting ﬂight in Kuwait appeared
in PaxIS database as a passenger arriving in Italy from India.second quarter, medians were 60, 12, 3 and less than one dengue
viremic person-days in Italy, Spain, France and Greece, respectively.
During the third quarter, medians for the same countries were 70,17, 4
and less than one dengue viremic person-days (Fig. 4). Slovenia is not
presented as no data for air-passengers were available.
Chikungunya viremic person-days estimates
A total of 17 non-EU countries and overseas territories of EU
Member States reported CHIKV transmission during at least once from
2003 to 2007. Quarterly chikungunya incidences were found for 3
countries: India, Mayotte and Reunion Island. Combined air-travellers
and quarterly chikungunya incidences were available only for India
using the Eurostat or OFOD databases. The model therefore computed
estimates for the whole EU only with air-travellers from India.
Separate estimates for Italy were obtained for air-travellers from India
and Reunion Island using the PaxIS database (Fig. 5).thick horizontal bar inside the gray boxes corresponds to themedian of the distribution.
The lower and upper limits of the gray boxes correspond to the 25 (Q1) and the 75
(Q3) percentiles of the distribution. The lower and upper whiskers correspond to:
xlower whisker=min {xi|xi≥Q1−1.5×(Q3−Q1)}, xupper whisker=max {xi|xi≤Q3+1.5×
(Q3−Q1)}. The small circles correspond to any data points which lie beyond the
extremes of the whiskers.
Fig. 4. Distributions of dengue viremic person-days arriving in EU Aedes albopictus-
infested areas by country of destination, second and third quarters, 2006. Note: see note
of Fig. 3 for box-plot element description.
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person-days among air-travellers arriving to all 27 EU member states
from India. Estimates were highest during the third and the second
quarters (100 and 67 person-days respectively). We estimated 6
viremic person-days spent by travellers arriving in Aedes-infested
areas, all in Italy.
Using 2006 PaxIS passenger data for the pairs India–Italy and
Reunion Island–Italy, we estimated respectively 8 and 2 viremic
person-days among travellers arriving in the Italian Aedes-infested
provinces during the second and the third quarters.
Discussion
Wehave attempted to quantify the risk of importation of DENV and
CHIKV to EU Member States by estimating the number of viremic
person-days spent by travellers in 2006 upon arrival in EU in general,
and in EU Aedes-infested areas in particular. The number of viremic
person-days during the two quarters when the vector is active in
Europe should be interpreted as the number of days during which a
viremic person can infect an Aedes mosquito in Europe.
Estimates were based on a model including the latest data on the
worldwide reported incidence of the diseases, air-passenger ﬂow from
endemic/epidemic countries to the EU, and proportion of the EUFig. 5. Number of non-EU countries and overseas EU territories with reported CHIKV aut
passenger data ﬂow for 2006.population living in Aedes-infested areas. We took into account the
proportion of asymptomatic infections, the likelihood of being viremic
upon arrival to an EUMember State and the duration of viremia. Other
studies have used mathematical modelling to estimate the risk of
dengue and chikungunya infection in travellers to Singapore (Massad
et al., 2008; Massad and Wilder-Smith, 2009). Their model includes
parameters taking into account the duration of stay of the traveller, as
well as entomological factors such as vector mortality. Whereas such
models can be very useful for risk assessment, their current
application at the EU level is limited due to scarce entomological
data. Our work takes into account passenger ﬂows from all endemic
countries, an aspect not addressed by previous studies.
We estimated that in 2006 the number of viremic person-days was
sizeable for both DENV and CHIKV. Considering the EU Aedes-infested
areas and the mosquito active period, we estimated a median number
of 169 and a point value of 6 viremic person-days for dengue and
chikungunya respectively.
Dengue estimates were highest among travellers arriving from
Asia and notably South-East Asia. Our geographical travel origin and
seasonal patterns of viremic travellers were similar to the patterns of
ill returned travellers with dengue reported by the GeoSentinel
Surveillance Network (Schwartz et al., 2008). Regarding the EU Aedes-
infested areas, Italy was clearly the most exposed EU Member State.
Mainly due to the presence of the vector in almost all its provinces,
Italy accounted for more than three quarters of all dengue viremic
person-days at any time during the period when local transmission
has the potential to be initiated.
Estimates of chikungunya viremic person-days were much lower
than those of dengue. If compared with DENV, fewer countries reported
CHIKV transmission. In general these countries are less popular
destinations for tourists. Chikungunya fever was a new or re-emerging
disease for many countries inwhich no speciﬁc surveillance systemwas
inplace before the 2005–2006 outbreaks in the IndianOcean. This led to
scarce chikungunya incidence data. However, our model showed that
Italy remains themostexposedEUMember Statewhen lookingatCHIKV
viremic person-days arriving in Aedes-infested areas.
Our estimates suggest that during the peak of the Indian outbreak
(quarters 2 and 3 of 2006) 8 chikungunya viremic person-days were
spent in the Italian Aedes-infested areas. Given that reported
chikungunya incidence in India was much lower in 2007 (source:
Directorate of National Vector Borne Disease Control Programme,
India), the correspondingnumber of viremic person-days spent in Italy
by air-travellers from India was probably lower as well in quarters 2
and 3 2007, while local transmission was initiated with an index caseochthonous infections, available chikungunya incidence for 2003–2007 and available
180 T. Seyler et al. / Epidemics 1 (2009) 175–184returning from India (Rezza et al., 2007). This could suggest that few
CHIK viremic person-days sufﬁce to trigger local transmission,
conﬁrming the high vector competence of A. albopictus for CHIKV.
As it happened for chikungunya, the possibility that local virus
transmission could occur in Europe also for dengue cannot be ruled
out. Dengue epidemics with A. albopictus as themain vector have been
already described (Efﬂer et al., 2005; Gratz, 2004; Michault, 1998), but
little is known about competence and capacity of A. albopictus for
dengue in temperate climates (for instance, by howmany days would
lower temperatures increase the extrinsic incubation period). The
possibility for better adaptation to the vector should be also
considered, as it was the case for CHIKV during the Reunion Island
epidemic (Tsetsarkin et al., 2007).
We are aware of the limitations to the precision of our estimates. A
ﬁrst limitation was related to the availability and completeness of inci-
dence data. For some countries which were known to have experienced
DENV or CHIKV transmission, no quarterly incidence datawere available.
Most notably, we could not ﬁnd data for Sub-Saharan Africa. In addition,
when data were available, case deﬁnitions or reporting criteria varied
across countries. In any case, data reported through surveillance systems
were far from exhaustive, and usually underestimated.
A second limitation was related to passenger data. Some routes
were not covered by the Eurostat or OFOD databases, for instance for
Reunion Island and Mayotte, two French overseas territories that
experienced chikungunya outbreaks in 2005–06, and for the French
Guyana, where dengue is known to be endemic. Both Euorstat and
OFOD report only direct ﬂights and the link is lost with the endemic
country when passengers make a ﬂight connection. This was only
partially offset by the use of PaxIS database for India–Italy and
Reunion Island–Italy routes, as far as chikungunya was concerned.
The above limitations may have led to lowering the estimates at
different degrees. However, other limitations listed below may have
led to inﬂating the estimates.
Disease incidence in air-travellers is probably lower than in general
population, and not equal, aswe assumed in ourmodel. It is reasonable
to consider that many travellers were either tourists or business
travellers, often staying in mosquito-free air-conditioned hotels and
using personal protection. However, these types of travellers would
havehigher risk of becoming sick and viremic than the local population
due to a lack of immunity from previous infections.
Another major limitation inﬂating our estimates was the decision
of ﬁxing high values for the proportion of asymptomatic infection
(80% for dengue) and for the duration of viremia (7 days for both
infections). In this case we opted for a worse scenario, but in reality,
one may argue that these variables would not be always so high.Appendix A. Symbol, description, value, and source of the parameters used.
Symbol Description of parameter
Inputs Ic
q Incidence of the disease in country c during quarter q as
reported by the local surveillance system
a Proportion of asymptomatic infections
t Likelihood for an infected individual of being viremic at the
moment of travelling (7 days of viraemia over a mean of
91.25 days in one quarter)
D Duration of viraemia expressed in days
Pc
q
→j Number of passengers travelling from country c to country
j by plane during quarter q
mj Proportion of population living in areas where the vector is
established within country j
Outputs Vc
q
→j Number of imported viraemic person-days travelling from
country of departure c to country of destination j during
quarter q
Vc
q
→mj Number of imported viraemic person-days arriving from
country of departure c to areas where the vector is
established in country j during quarter qFinally the decision of taking on average half of viremia duration
being spent upon arrival in the EU did not take into account that, for
symptomatic infections, most of the days of viremia overlap with
symptoms. In such a situation, the person might decide to delay the
ﬂight and spend in fact the whole viremic period outside of the EU.
Our estimates provide useful information to focus surveillance and
control measures depending of the period of the year, the endemic
country of travel origin and the Member State of travel destination.
More complete and accurate data are needed, both with regards to
disease surveillance and passenger ﬂow.
Until more detailed risk assessments are undertaken, it is
important for travellers to avoid CHIKV or DENV infections through
personal protection when visiting endemic countries. Upon the
travellers' return, the capacity for timely diagnosis and implementa-
tion of vector control measures should be considered a priority in EU
areas harbouring the vector, particularly in Italy, where the vector is
widespread during the summer.
Monitoring the introduction of the vector in newareas and enabling
rapid containment of its establishment and spread are equally
important measures to limit the risk of experiencing (or re-experien-
cing, for chikungunya) local transmission in continental Europe.
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0.8 0.15 Porter et al. (2005)
Perrau et al. (2007)
0.0767 0.0767 Dayal-Drager (2004)
7 7 Dayal-Drager (2004)
See Fig. 2 (or Table A1) See Fig. 5 (or Table A2) Eurostat, ICAO, IATA
See Table 1 See Table 1 Based on Scholte and
Schaffner (2007)
Distributions Point estimates Model
Distributions Point estimates Model
Table A1
Countries and overseas EU territories with reported DENV autochthonous infections, available dengue incidence for 2003–2007 and available passenger data ﬂow for 2006.
Geographic
area
Countries reporting DENV
autochthonous infections (2003–2007)
Countries reporting DENV
autochthonous infections (2003–2007)
and available air-passenger data (2006)
Countries with available quarterly
dengue incidence data (2003–2007)
Countries with available quarterly
dengue incidence data (2003–2007)
and air-passenger data (2006)
[Nb of countries] [Nb of countries] (air-passengers to
EU in 2006)
[Nb of countries] [Nb of countries] (air-passengers to
EU in 2006)
All countries [98] [75] (27525137) [54] [47] (21774978)
North
America ($)
Mexico Mexico Mexico Mexico
[1] [1] (1480553) [1] [1] (1480553)
Central
America
Belize, Costa Rica, El Salvador,
Guatemala, Honduras, Nicaragua,
Panama
Costa Rica, Guatemala, Honduras,
Nicaragua, Panama
Belize, Costa Rica, El Salvador,
Guatemala, Honduras, Nicaragua,
Panama
Costa Rica, Guatemala, Honduras,
Nicaragua, Panama
[7] [5] (234331) [7] [5] (234331)
The Caribbean Anguilla, Antigua and Barbuda, Aruba,
Bahamas, Barbados, British Virgin
Islands, Cayman Islands, Cuba,
Dominica, Dominican Republic,
Grenada, Guadeloupe, Haiti, Jamaica,
Martinique, Montserrat, Puerto Rico,
St. Kitts and Nevis, St. Lucia, St. Vincent
and the Grenadines, Turks and Caicos
Islands, Trinidad and Tobago
Anguilla, Antigua and Barbuda, Aruba,
Bahamas, Barbados, British Virgin
Islands, Cayman Islands, Cuba,
Dominica, Dominican Republic,
Grenada, Haiti, Jamaica, Puerto Rico,
St. Kitts and Nevis, St. Lucia, St. Vincent
and the Grenadines, Turks and Caicos
Islands, Trinidad and Tobago
Anguilla, Aruba, Bahamas, Barbados,
British Virgin Islands, Cayman Islands,
Cuba, Dominica, Dominican Republic,
Grenada, Jamaica, Montserrat, Puerto
Rico, St. Kitts and Nevis, St. Lucia,
St. Vincent and the Grenadines, Turks
and Caicos Islands, Trinidad and Tobago
Anguilla, Aruba, Bahamas, Barbados,
British Virgin Islands, Cayman Islands,
Cuba, Dominica, Dominican Republic,
Grenada, Jamaica, Puerto Rico, St. Kitts
and Nevis, St. Lucia, St. Vincent and
the Grenadines, Turks and Caicos
Islands, Trinidad and Tobago
[22] [19] (3592968) [18] [17] (3448884)
South
America
Argentina, Bolivia, Brazil, Chile,
Colombia, Ecuador, Guyana, French
Guyana, Paraguay, Peru, Suriname,
Venezuela
Argentina, Bolivia, Brazil, Chile,
Colombia, Ecuador, Guyana, Paraguay,
Peru, Suriname, Venezuela
Argentina, Bolivia, Brazil, Chile,
Colombia, Ecuador, Guyana, French
Guyana, Paraguay, Peru, Suriname,
Venezuela
Argentina, Bolivia, Brazil, Chile,
Colombia, Ecuador, Guyana, Paraguay,
Peru, Suriname, Venezuela
[12] [11] (4870162) [12] [11] (4870162)
Sub-Saharan
Africa
Angola, Burkina Faso, Cameroon,
Djibouti, Gabon, Guinea, Ivory Coast,
Kenya, Lesotho, Mozambique, Nigeria,
Senegal, Somalia, Sudan
Angola, Burkina Faso, Cameroon,
Djibouti, Gabon, Guinea, Ivory Coast,
Kenya, Mozambique, Nigeria, Senegal,
Sudan
[14] [12] (2322874) [0] [0] (NA)
Indian ocean
islands
Comoros, Madagascar, Mayotte,
Mauritius, Reunion Island, Seychelles
Comoros, Madagascar, Mauritius,
Seychelles
[6] [4] (970167) [0] [0] (NA)
Middle East Saudi Arabia, Yemen Saudi Arabia, Yemen
[2] [2] (336430) [0] [0] (NA)
South-Central
Asia
Afghanistan, Bangladesh, Bhutan, India,
Maldives, Nepal, Pakistan, Sri Lanka
Afghanistan, Bangladesh, India,
Maldives, Nepal, Pakistan, Sri Lanka
Bangladesh, India, Maldives, Nepal,
Sri Lanka
Bangladesh, India, Maldives,
Nepal, Sri Lanka
[8] [7] (3650407) [5] [5] (3231946)
China, Taiwan China, Taiwan China, Taiwan China China
[2] [2] (4526816) [1] [1] (4009095)
South-East
Asia
Brunei Darussalam, Cambodia,
Indonesia, Lao People's Democratic
Republic, Malaysia, Myanmar,
Philippines, Singapore, Thailand,
Timor-Leste, Vietnam
Brunei Darussalam, Indonesia, Malaysia
Myanmar, Philippines, Singapore,
Thailand, Vietnam
Cambodia, Indonesia, Lao People's
Democratic Republic, Malaysia,
Myanmar, Philippines, Singapore,
Thailand, Timor-Leste, Vietnam
Indonesia, Malaysia, Myanmar,
Philippines, Singapore,
Thailand, Vietnam
[11] [8] (4566820) [10] [7] (4500007)
Oceania and
Paciﬁc
islands
Australia, Cook Islands, Easter Islands,
Fiji, Hawaii, Micronesia, Marshall
Islands, New Guinea, New Caledonia,
French Polynesia, Palau, Papua, Samoa
Australia, Fiji, French Polynesia,
New Caledonia
[13] [4] (973609) [0] [0] (NA)
($) sporadic local transmission was also reported in Texas (USA).
Table A2
Countries and overseas EU territories with reported CHIKV autochthonous infections, available chikungunya incidence for 2003–2007 and available passenger data ﬂow for 2006.
Geographic area Countries reporting CHIKV
autochthonous infections
(2003–2007)
Countries reporting CHIKV
autochthonous infections
(2003–2007) and available
air-passenger data (2006)
Countries with available quarterly
chikungunya incidence data
(2003–2007)
Countries with available quarterly
chikungunya incidence data (2003–
2007) and air-passenger data (2006)
[Nb of countries] [Nb of countries] (air-passengers to
EU in 2006)
[Nb of countries] [Nb of countries] (air-passengers to
EU in 2006)
All countries 17 15 3 2
South-East
Asia Islands
Indonesia, Malaysia, Singapore Indonesia, Malaysia, Singapore
[3] [3] (2268737) [0] [0]
South-Central
Asia
India, Maldives, Sri Lanka India, Maldives, Sri Lanka India India
[3] [3] (3122247) [1] [1] (2593562)
Sub-Saharan
Africa
Gabon, Cameroon, Kenya, Senegal,
Sudan
Gabon, Cameroon, Kenya, Senegal,
Sudan
[5] [5] (1361047) [0] [0]
East Africa
Islands
Comoros, Madagascar, Mayotte,
Mauritius, La Réunion, Seychelles
Comoros, Madagascar, Mauritius,
Seychelles
Mayotte, La Réunion La Réunion
[6] [4] (970167) [2] [1] (only passenger ﬂow to Italy:
1259) ($)
($) PaxIS database.
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Appendix B. Quarterly distributions of incidence of cases per 100
^
000 for the years 2003–
^
2007 by group of countries with similar quarterly dengue incidence rates and seasonal incidence pattern.
Continent or
subcontinent
Group countriesa Quarter 1 (January–March) Quarter 2 (April–June) Quarter 3 (July–September) Quarter 4 (October–December)
Mean Variance Min Max Mean Variance Min Max Mean Variance Min Max Mean Variance Min Max
Asia 1 Bangladesh, India,
Myanmar,
Sri Lanka
2.56 25.04 0.00 17.80 3.33 15.70 0.00 12.89 6.46 47.38 0.07 19.37 4.83 48.53 0.03 24.22
2 Maldives 85.90 8508.49 3.04 228.27 90.27 10064.16 0.00 255.62 94.59 5606.17 0.61 176.90 115.81 6016.25 7.90 193.01
3 Cambodia, Lao People's
Democratic Republic,
Philippines, Thailand,
Viet Nam
7.98 17.10 1.45 18.66 23.16 159.07 4.34 57.60 37.49 1538.71 12.53 203.24 14.58 61.91 4.01 34.49
4 Malaysia, Singapore 44.22 440.70 17.22 70.36 36.95 104.91 18.96 54.35 39.36 1744.73 13.46 144.24 27.48 644.83 10.42 84.19
5 Indonesia, Timor-Leste 24.87 535.40 0.00 81.94 8.84 108.66 0.00 30.83 3.09 14.08 0.00 9.23 5.79 20.21 0.00 15.12
6 China, Nepal 5.90E−05 1.50E−08 0.00 3.80E−04 1.40E−03 1.30E−05 0.00 0.01 8.00E−03 3.20E−04 0.00 0.05 0.01 9.20E−04 0.00 0.09
North
America
7 Mexico 6.25 26.76 1.48 14.30 2.94 5.94 0.70 6.73 5.60 21.49 1.33 12.81 4.99 17.05 1.18 11.41
Central
America
8 Belize, Nicaragua,
Guatemala, Panama
19.37 963.00 0.00 140.74 5.45 36.62 0.00 19.80 10.57 132.35 0.00 37.65 10.51 132.33 0.00 33.54
9 Costa Rica, El Salvador,
Honduras
101.40 4182.15 34.14 275.99 47.75 927.58 16.07 129.97 90.85 3357.37 30.59 247.28 80.93 2664.29 27.25 220.29
America
Caribbeanb
10 Cuba, Jamaica, Saint Lucia,
Saint Vincent and the
Grenadines, Bahamas (Q 1–4),
Anguilla (Q 1 and 4),
Aruba (Q 1 and 3),
British Virgin Islands,
Cayman Islands (Q 1),
Grenada (Q 3 and 4),
Saint Kitts and Nevis
(Q 1, 3 and 4), Montserrat
(Q 3), Turks and
Caicos Islands (Q 4)
4.00 104.38 0.00 62.84 1.48 10.24 0.00 11.76 2.01 28.61 0.00 31.69 2.59 30.64 0.00 24.77
11 Barbados, Dominican
Republic, Puerto Rico,
Trinidad and Tobago
(Q 1–4), Grenada (Q 2),
Dominica (Q 3)
19.38 373.14 0.00 60.74 9.08 53.36 0.00 25.71 24.85 962.07 0.00 140.51 37.16 2268.43 0.00 192.22
South
America
12 Guyana 4.05 1.96 2.66 5.86 9.24 46.27 2.00 16.78 2.77 1.96 0.53 4.13 0.08 0.03 0.00 0.40
13 Brazil, Colombia,
Suriname, Venezuela
51.21 1900.69 2.23 158.35 37.19 1190.52 2.00 137.64 28.99 2174.16 3.12 220.49 30.13 686.63 1.78 119.15
14 Bolivia, Ecuador, Peru 26.74 386.50 7.65 65.69 13.44 59.53 4.03 26.49 1.95 3.65 0.20 7.11 7.28 93.42 0.34 33.57
15 Paraguay 49.36 8202.88 1.02 209.69 38.29 4954.77 0.75 162.89 6.05 122.17 0.13 25.63 13.99 659.08 0.29 59.43
16 Argentina, Chile 0.48 1.61 0.00 4.08 0.29 0.54 0.00 2.37 0.09 0.06 0.00 0.81 0.13 0.12 0.00 1.11
Note:
a Countries for which dengue virus circulation was reported, but no data of dengue fever incidence on human population were available: - Asia: Afghanistan, Bhutan, Brunei Darussalam, Pakistan, Saudi Arabia, Taiwan, Yemen - Oceania:
Australia - Paciﬁc: Cook Islands, Easter Islands, Fiji, Hawaii, Micronesia, Marshall Islands, New Guinea, New Caledonia, French Polynesia, Palau, Papua, Samoa - Africa: Angola, Burkina Faso, Cameroon, Comoros, Djibouti, Gabon, Guinea, Ivory
Coast, Kenya, Lesotho, Madagascar, Mauritius, Mayotte, Mozambique, Nigeria, Réunion Island, Senegal, Seychelles, Somalia, Sudan.
b Carribean islands were very variated in terms of incidence. One country may be in both groups 10 and 11 according to the quarter. In parenthesis the quarter for which the country contributed to the distribution. Countries and quarters
with zero incidence reported: Antigua and Barbuda (Q 1–4), Aruba (Q 2, 4), British Virgin Islands, Cayman Islands (Q 2, 3 and 4), Dominica, Montserrat (Q 1, 2 and 4), Grenada (Q 1), Saint Kitts and Nevis (Q 2), Turks and Caicos Islands (Q 1, 2
and 3).
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Appendix C. Estimated distribution of dengue viremic person-
^
days among travellers by country of departure from the American continent.
Country Quarter 1 (January–March) Quarter 2 (April–June) Quarter 3 (July–September) Quarter 4 (October–December)
Min 25% Median 75% Max Min 25% Median 75% Max Min 25% Median 75% Max Min 25% Median 75% Max
Brazil 22 173 339 559 1227 15 86 186 378 963 21 56 135 301 1299 12 93 155 260 771
Dominican Rep. 2 26 66 137 325 b1 b1 b1 1 3 b1 23 72 150 654 b1 23 87 220 744
Venezuela 5 39 77 127 303 4 26 50 93 229 7 21 52 106 452 4 20 40 75 196
Costa Rica 21 40 60 87 169 10 19 29 43 84 20 37 55 80 154 17 31 45 66 131
Colombia 5 25 51 85 202 3 16 35 59 150 4 15 34 67 271 2 12 23 40 111
Mexico 6 13 22 33 59 4 8 12 20 35 8 17 27 42 74 6 12 18 30 53
Barbados b1 7 21 40 93 2 17 32 49 107 b1 b1 b1 b1 1 b1 8 25 63 190
Suriname b1 7 15 27 59 b1 6 10 18 48 1 4 10 22 99 b1 5 8 14 45
Peru 7 14 22 33 61 4 7 11 15 25 b1 b1 1 3 7 b1 2 4 9 30
Ecuador 6 12 20 30 55 3 6 9 13 21 b1 b1 1 3 7 b1 2 4 8 27
Trinidad and Tobago b1 3 7 15 31 b1 2 3 5 12 b1 1 5 14 46 b1 2 6 14 49
British Virgin Isl. b1 b1 b1 b1 b1 b1 3 6 10 23 b1 3 11 29 111 b1 b1 b1 b1 b1
Puerto Rico b1 b1 2 4 9 b1 b1 2 3 6 b1 b1 3 8 30 b1 b1 4 10 41
Bolivia b1 b1 1 2 3 b1 b1 b1 b1 1 b1 b1 b1 b1 1 b1 b1 2 4 12
Panama b1 b1 b1 3 20 b1 b1 b1 1 3 b1 b1 b1 2 6 b1 b1 b1 2 5
Cuba b1 b1 b1 10 166 0 0 0 0 0 b1 b1 b1 b1 3 b1 b1 b1 6 62
St. Kitts and Nevis b1 b1 b1 b1 b1 b1 b1 b1 4 31 b1 b1 b1 1 31 b1 b1 b1 b1 b1
Cayman Islands b1 b1 b1 b1 2 b1 b1 b1 1 10 b1 b1 b1 b1 8 b1 b1 b1 2 21
Jamaica b1 b1 b1 3 45 b1 b1 b1 b1 2 b1 b1 b1 b1 b1 b1 b1 b1 b1 3
Bahamas b1 b1 b1 b1 5 0 0 0 0 0 b1 b1 b1 5 99 b1 b1 b1 b1 3
Saint Lucia b1 b1 b1 1 22 b1 b1 b1 b1 3 0 0 0 0 0 b1 b1 b1 b1 6
Argentina b1 b1 b1 b1 13 b1 b1 b1 b1 7 b1 b1 b1 b1 2 b1 b1 b1 b1 3
Guatemala b1 b1 b1 b1 b1 0 0 0 0 0 0 0 0 0 0 b1 b1 b1 b1 b1
Aruba b1 b1 b1 b1 9 0 0 0 0 0 b1 b1 b1 b1 6 b1 b1 b1 b1 b1
Chile b1 b1 b1 b1 5 b1 b1 b1 b1 2 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1
Anguilla b1 b1 b1 b1 b1 0 0 0 0 0 b1 b1 b1 b1 9 0 0 0 0 0
St Vinc. and Gren. b1 b1 b1 b1 1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1
Honduras 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 b1 b1 b1 b1 b1
Guyana b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 0 0 0 0 0 b1 b1 b1 b1 b1
Paraguay 0 0 0 0 0 b1 b1 b1 b1 b1 0 0 0 0 0 b1 b1 b1 b1 b1
Nicaragua 0 0 0 0 0 0 0 0 0 0 b1 b1 b1 b1 b1 0 0 0 0 0
Appendix D. Estimated distribution of dengue viremic person-
^
days among travellers by country of departure from the Asian continent.
Country Quarter 1 (January–March) Quarter 2 (April–June) Quarter 3 (July–September) Quarter 4 (October–December)
Min 25% Median 75% Max Min 25% Median 75% Max Min 25% Median 75% Max Min 25% Median 75% Max
Singapore 82 147 197 240 328 101 159 188 221 285 71 121 204 340 755 47 78 126 191 380
Thailand 15 35 51 72 141 35 92 121 171 328 72 145 210 328 1103 24 54 74 108 194
Malaysia 43 73 99 130 174 44 70 83 98 127 29 52 87 140 309 18 30 46 72 143
Maldives 3 23 61 119 257 b1 16 41 89 206 b1 24 43 68 122 6 41 67 99 146
India b1 b1 6 35 172 b1 5 20 38 107 b1 12 31 65 156 b1 7 27 57 203
Viet Nam 1 4 5 7 12 3 8 13 19 34 9 17 28 46 150 3 6 9 12 22
Philippines 1 3 5 7 12 3 9 14 19 35 8 15 23 39 123 2 4 6 8 15
Indonesia b1 3 8 14 35 b1 b1 3 6 15 b1 b1 b1 2 5 b1 1 2 4 7
Sri Lanka b1 b1 b1 2 17 b1 b1 2 3 10 b1 2 4 7 19 b1 b1 2 4 19
Bangladesh b1 b1 b1 b1 7 b1 b1 b1 1 4 b1 b1 2 3 7 b1 b1 b1 2 6
China b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1
Myanmar b1 b1 b1 b1 b1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Nepal b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1 b1
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